NCT06905873View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

January 31, 2026

Conditions
Vitiligo
Interventions
DRUG

FB102

Route of administration- Intravenous (IV)

DRUG

Placebo

Route of administration- Intravenous (IV)

Trial Locations (8)

1010

RECRUITING

Optimal Clinical Trials Central, Auckland

2010

RECRUITING

Skin & Cancer Foundation Australia - The Skin Hospital, Darlinghurst

2120

RECRUITING

Momentum Pukehoke, Auckland

2289

RECRUITING

Novatrials, Kotara

4102

RECRUITING

Veracity Clinical Research, Woolloongabba

4151

RECRUITING

Cornerstone Dermatology, Coorparoo

5018

RECRUITING

PCRN Wellington, Wellington

0632

RECRUITING

Optimal Clinical Trials North, Auckland

Sponsors
All Listed Sponsors
lead

Forte Biosciences, Inc.

INDUSTRY

NCT06905873 - A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo | Biotech Hunter | Biotech Hunter